Please assess the completion status of the following clinical trial:

Trial Title: Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic multiple myeloma, meeting the following criteria at original diagnosis:~  * Bone marrow plasmacytosis with ≥ 10% plasma cells or sheets of plasma cells or biopsy proven plasmacytoma~ * Symptomatic disease (e.g.,anemia, hypercalcemia, bone disease, or renal dysfunction) that requires the initiation of therapy~* Measurable diseases assessed by one of the following:~  * Monoclonal plasma cells detectable in the bone marrow~ * Monoclonal serum spike detectable by serum protein electrophoresis or immunofixation~ * Monoclonal protein detectable in the urine by electrophoresis or immunofixation~ * Abnormal levels of the serum free light chains with an abnormal ratio between kappa and lambda~* Progressive disease after ≥ 1 prior therapy for myeloma~* Previously treated with ≤ 10 courses (30 weeks) of bortezomib and had no disease progression during therapy OR completed bortezomib therapy within the past 6 weeks~  * No prior discontinuation of bortezomib therapy due to drug intolerance~* No known brain metastases~* No intracranial edema, intracranial metastasis, or active epidural disease~  * Patients with lytic lesions of the cranium secondary to myeloma are eligible~* ECOG performance status 0-2~* Life expectancy \> 6 months~* ANC ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* Bilirubin normal~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Creatinine ≤ 2 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No peripheral neuropathy \> NCI toxicity grade 2~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to obatoclax mesylate or bortezomib~* No concurrent uncontrolled illness including, but not limited to the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia, including QTc \> 450 msec~ * Psychiatric illness/social situations that would limit compliance with study requirements~* No history of seizure disorder~* No other neurological disorder or dysfunction that, in the opinion of the investigator, would confound the evaluation of neurologic and other adverse events associated with obatoclax mesylate~* At least 14 days since prior chemotherapy and recovered~* More than 28 days since prior experimental drugs and/or investigational agents~* No concurrent CYP interactive medications~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent anticancer therapy~  * Growth factors and bisphosphonates are allowed as medically indicated~ * Prednisone (≤ 10 mg per day) allowed provided there has been no dose increase within the past 2 weeks~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy) (Type: EXPERIMENTAL): Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues